Crossmark Global Holdings’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.67M | Hold |
69,380
| – | – | 0.02% | 506 |
|
|
2026
Q1 | $1.95M | Sell |
69,380
-2,948
| -4% | -$78.5K | 0.03% | 438 |
|
|
2025
Q4 | $1.8M | Sell |
72,328
-529
| -0.7% | -$13.3K | 0.03% | 456 |
|
|
2025
Q3 | $1.86M | Buy |
72,857
+676
| +0.9% | +$16.7K | 0.03% | 471 |
|
|
2025
Q2 | $1.75M | Sell |
72,181
-90
| -0.1% | -$2.1K | 0.03% | 461 |
|
|
2025
Q1 | $1.83M | Sell |
72,271
-3,001
| -4% | -$78.5K | 0.03% | 446 |
|
|
2024
Q4 | $2M | Hold |
75,272
| – | – | 0.04% | 398 |
|
|
2024
Q3 | $2.18M | Sell |
75,272
-2,828
| -4% | -$82.5K | 0.04% | 392 |
|
|
2024
Q2 | $2.19M | Sell |
78,100
-433
| -0.6% | -$11.9K | 0.04% | 383 |
|
|
2024
Q1 | $2.18M | Sell |
78,533
-330
| -0.4% | -$9.16K | 0.04% | 401 |
|
|
2023
Q4 | $2.27M | Buy |
78,863
+1,107
| +1% | +$33.5K | 0.05% | 367 |
|
|
2023
Q3 | $2.58M | Sell |
77,756
-96,131
| -55% | -$3.4M | 0.06% | 331 |
|
|
2023
Q2 | $6.27M | Buy |
173,887
+18,474
| +12% | +$719K | 0.14% | 186 |
|
|
2023
Q1 | $6.34M | Buy |
155,413
+2,547
| +2% | +$110K | 0.15% | 177 |
|
|
2022
Q4 | $7.83M | Sell |
152,866
-572
| -0.4% | -$27.4K | 0.2% | 139 |
|
|
2022
Q3 | $6.71M | Sell |
153,438
-1,252
| -0.8% | -$60.8K | 0.19% | 138 |
|
|
2022
Q2 | $8.11M | Sell |
154,690
-213
| -0.1% | -$10.9K | 0.21% | 124 |
|
|
2022
Q1 | $8.02M | Buy |
154,903
+98,959
| +177% | +$5.13M | 0.18% | 151 |
|
|
2021
Q4 | $3.3M | Sell |
55,944
-2,631
| -4% | -$130K | 0.07% | 266 |
|
|
2021
Q3 | $2.52M | Buy |
58,575
+1,899
| +3% | +$84.1K | 0.06% | 325 |
|
|
2021
Q2 | $2.22M | Sell |
56,676
-143,796
| -72% | -$5.59M | 0.05% | 349 |
|
|
2021
Q1 | $7.26M | Buy |
200,472
+124,601
| +164% | +$4.42M | 0.18% | 139 |
|
|
2020
Q4 | $2.79M | Sell |
75,871
-204,453
| -73% | -$7.5M | 0.07% | 297 |
|
|
2020
Q3 | $9.76M | Sell |
280,324
-15,738
| -5% | -$552K | 0.27% | 89 |
|
|
2020
Q2 | $9.19M | Sell |
296,062
-11,368
| -4% | -$386K | 0.27% | 89 |
|
|
2020
Q1 | $9.52M | Sell |
307,430
-3,776
| -1% | -$129K | 0.34% | 78 |
|
|
2019
Q4 | $11.6M | Sell |
311,206
-2,644
| -0.8% | -$94.2K | 0.32% | 83 |
|
|
2019
Q3 | $10.7M | Sell |
313,850
-81,949
| -21% | -$2.98M | 0.31% | 80 |
|
|
2019
Q2 | $16.3M | Buy |
395,799
+10,030
| +3% | +$398K | 0.46% | 43 |
|
|
2019
Q1 | $15.5M | Sell |
385,769
-1,421
| -0.4% | -$56.9K | 0.44% | 42 |
|
|
2018
Q4 | $16M | Buy |
387,190
+17,871
| +5% | +$742K | 0.5% | 36 |
|
|
2018
Q3 | $15.4M | Sell |
369,319
-2,674
| -0.7% | -$103K | 0.39% | 48 |
|
|
2018
Q2 | $12.8M | Sell |
371,993
-18,009
| -5% | -$615K | 0.34% | 55 |
|
|
2018
Q1 | $13.1M | Sell |
390,002
-6,672
| -2% | -$229K | 0.34% | 59 |
|
|
2017
Q4 | $13.6M | Buy |
396,674
+1,458
| +0.4% | +$49.7K | 0.33% | 63 |
|
|
2017
Q3 | $13.4M | Buy |
+395,216
| New | +$12.7M | 0.35% | 57 |
|
|
2016
Q3 | $13.4M | Buy |
+395,216
| New | +$13.2M | 0.35% | 57 |
|
Other funds holding PFE
Crossmark Global Holdings's PFE Position: Q2 2026 in Review
Crossmark Global Holdings held its Pfizer (PFE) position steady in Q2 2026 at 69,380 shares worth $1.67M. The position accounts for 0.02% of the portfolio, ranked #506.
Crossmark Global Holdings first reported a position in PFE in Q3 2016 and has held it in 37 quarters since. The position peaked at $16.3M in Q2 2019. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Crossmark Global Holdings held 69,380 shares of Pfizer worth $1.67M as of Q2 2026.
- Crossmark Global Holdings left its Pfizer share count unchanged in Q2 2026.
- Pfizer made up 0.02% of Crossmark Global Holdings's portfolio in Q2 2026, its #506 holding.
- Crossmark Global Holdings first reported a position in Pfizer in Q3 2016 and has held it in 37 quarters since.
- Crossmark Global Holdings's Pfizer position peaked at $16.3M in Q2 2019.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.